Q.1.
The driving force behind the conceptualization of in vivo culturing of tissues was the limited number of donors available and graft-rejection by the immune system.
Q.2.
Prosthetic devices are capable of restoring normal function, and the number of organ donors is always way less than required.
Q.3.
Which is the Competent Authority for tissues and cells in the United Kingdom?
Q.4.
What is the Goal of Tissue Engineering?
Q.5.
Title ______________ constitutes of a comprehensive regulatory Framework for the producers of human cells, tissues, and cellular and tissue-based products (HCT/Ps).
Q.6.
Which Act governs the manufacture of HCT/Ps?
Q.7.
Umbilical cord blood stem cells are an example ofHCT/Ps that meet the criteria in Titleof CFR part 1271.
Q.8.
_____________ need to register with FDA under Titleof Code of Federal Regulations (CFR).
Q.9.
Name oneHCT/P which cannot be imported.
Q.10.
Which of the following Tissue Engineering products has been approved by the European Medicines Agency (EMA) as an Advanced Therapy medicinal product (Drug)?